61
Effenhauser Carlo Stefan, Manz Andreas: (De) Transdermales system, (En) Transdermal system. Novartis, Effenhauser Carlo Stefan, Manz Andreas, NOVARTIS, June 13, 1996: WO/1996/017648 (1 worldwide citation)

(EN) A transdermal system (1) for delivering a substance through the skin (2) has a reservoir (11) which stores the substance for delivery and a transfer device which in operation is connected to both the reservoir and the skin by means of passage openings. This transfer device comprises a sheet sub ...


62
Parminder Singh, Eun Soo Lee, Amit K Jain: Transdermal administration of tamsulosin. Corium International, Judy M Mohr, McDermott Will & Emery, April 4, 2017: US09610253

In an aspect of the invention, a composition for making a patch for the transdermal delivery of tamsulosin is provided. The composition comprises (a) at least about 1 wt % tamsulosin or a pharmaceutically acceptable salt of tamsulosin, (b) at least about 40 wt % polyisobutylene adhesive or hydrophob ...


63
Curtis Wright, Benjamin Oshlack, Christopher Breder: Pharmaceutical formulation containing gelling agent. Purdue Pharma, The P F Laboratories, Purdue Pharmaceuticals, Lowenstein Sandler, July 4, 2017: US09693961

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart ...


64
Curtis Wright, Benjamin Oshlack, Christopher Breder: Pharmaceutical formulation containing gelling agent. Purdue Pharma, The P F Laboratories, Purdue Pharmaceuticals, Lowenstein Sandler, January 30, 2018: US09877924

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart ...


65
Ralph G Dacey Jr, Nathan P Myhrvold, Michael A Smith, Lowell L Wood Jr, Victoria Y H Wood, Gregory J Zipfel, Gregory J Della Rocca, Colin P Derdeyn, Joshua L Dowling, Eleanor V Goodall, Roderick A Hyde, Muriel Y Ishikawa, Jordin T Kare, Eric C Leuthardt: Method and system for modulating neural activity. Gearbox, October 17, 2017: US09789315

Methods and related systems for modulating neural activity by cyclically modulating neural activity in peripheral neural structures are disclosed. Neural activity may be modulated cyclically by stimuli delivered via various types of stimulus sources. In an aspect, activity of a sensory nerve is modu ...


66

67
Robert F Reder, Paul D Goldenheim, Robert F Kaiko: Method of providing sustained analgesia with buprenorphine. PURDUE PHARMA, Jones Day, May 9, 2017: US09642850

A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the a ...


68
Tarik Soliman, Laura M Hales, Daniel B Hall, Christopher So, Howard P Sard, Vishnumurthy Hegde: Therapeutic vitamin D conjugates. Extend Biosciences, Kaplan IP Law P C, Jonathan M Kaplan, March 7, 2017: US09585934

The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon ...


69
Tarik Soliman, Laura M Hales, Daniel B Hall, Howard Sard, Vishnumurthy Hegde: Insulin vitamin D conjugates. Extend Biosciences, Kaplan IP Law P C, Jonathan M Kaplan, April 11, 2017: US09616109

The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbo ...


70
Guy Dipierro: Biosynchronous transdermal drug delivery. CHRONO THERAPEUTICS, Shay Glenn, January 31, 2017: US09555227

Systems and methods for synchronizing the administration of compounds with the human body's natural circadian rhythms and addiction rhythms to counteract symptoms when they are likely to be at their worst by using an automated and pre programmable transdermal or other drug administration system.